ProShares UltraShort NASDAQ Biotechnology
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
26% more capital invested
Capital invested by funds: $858K [Q3] → $1.08M (+$221K) [Q4]
6.84% more ownership
Funds ownership: 22.81% [Q3] → 29.65% (+6.84%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
14% less funds holding
Funds holding: 7 [Q3] → 6 (-1) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BIS.
Financial journalist opinion
Neutral
ETF Trends
11 hours ago
Top Performing Leveraged/Inverse ETFs: 05/11/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Neutral
Seeking Alpha
2 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
ETF Trends
5 months ago
Top Performing Leveraged/Inverse ETFs: 11/17/2024
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Charts implemented using Lightweight Charts™